FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099681868> ?p ?o ?g. }

• W2099681868 endingPage "1024" @default.
• W2099681868 startingPage "1009" @default.
• W2099681868 abstract "There is increasing evidence that sensitization of the androgen receptor (AR) signaling pathway contributes to the failure of androgen ablation therapy for prostate cancer, and that direct targeting of the AR may be a useful therapeutic approach. To better understand how AR function could be abrogated in prostate cancer cells, we have developed a series of putative dominant-negative variants of the human AR, containing deletions or mutations in activation functions AF-1, AF-5, and/or AF-2. One construct, AR inhibitor (ARi)-410, containing a deletion of AF-1 and part of AF-5 of the AR, had no intrinsic transactivation activity but inhibited wild-type AR (wtAR) in a ligand-dependent manner by at least 95% when transfected at a 4:1 molar ratio. ARi-410 was an equally potent inhibitor of gain-of-function AR variants. Ectopic expression of ARi-410 inhibited the proliferation of AR-positive LNCaP cells, but not AR-negative PC-3 cells. Whereas ARi-410 also marginally inhibited progesterone receptor activity, this was far less pronounced than the effect on AR (50% vs. 95% maximal inhibition, respectively), and there was no inhibition of either vitamin D or estrogen receptor activity. In the presence of ligand, ARi-410 interacted with wtAR, and both receptors translocated into the nucleus. Whereas the amino-carboxy terminal interaction was not necessary for optimal dominant-negative activity, disruption of dimerization through the ligand binding domain reduced the efficacy of ARi-410. In addition, although inhibition of AR function by ARi-410 was not dependent on DNA binding, the DNA binding domain was required for dominant-negative activity. Taken together, our results suggest that interaction between ARi-410 and the endogenous AR in prostate cancer cells, potentially through the DNA binding and ligand binding domains, results in a functionally significant reduction in AR signaling and AR-dependent cell growth." @default.
• W2099681868 created "2016-06-24" @default.
• W2099681868 creator A5005692759 @default.
• W2099681868 creator A5011763388 @default.
• W2099681868 creator A5015580865 @default.
• W2099681868 creator A5016640394 @default.
• W2099681868 creator A5020285542 @default.
• W2099681868 creator A5021075431 @default.
• W2099681868 creator A5042201449 @default.
• W2099681868 creator A5050075947 @default.
• W2099681868 creator A5063165070 @default.
• W2099681868 creator A5078763633 @default.
• W2099681868 creator A5080276064 @default.
• W2099681868 creator A5080763146 @default.
• W2099681868 date "2006-05-01" @default.
• W2099681868 modified "2023-09-29" @default.
• W2099681868 title "Suppression of Androgen Receptor Signaling in Prostate Cancer Cells by an Inhibitory Receptor Variant" @default.
• W2099681868 cites W1580523172 @default.
• W2099681868 cites W1604175000 @default.
• W2099681868 cites W1828013187 @default.
• W2099681868 cites W1967932707 @default.
• W2099681868 cites W1969241521 @default.
• W2099681868 cites W1979576412 @default.
• W2099681868 cites W1985827132 @default.
• W2099681868 cites W1995296127 @default.
• W2099681868 cites W1997315176 @default.
• W2099681868 cites W2002418723 @default.
• W2099681868 cites W2003955264 @default.
• W2099681868 cites W2005658600 @default.
• W2099681868 cites W2007589116 @default.
• W2099681868 cites W2017223203 @default.
• W2099681868 cites W2021463266 @default.
• W2099681868 cites W2030819637 @default.
• W2099681868 cites W2032593619 @default.
• W2099681868 cites W2035179289 @default.
• W2099681868 cites W2037237927 @default.
• W2099681868 cites W2041170006 @default.
• W2099681868 cites W2041781038 @default.
• W2099681868 cites W2056731938 @default.
• W2099681868 cites W2058469225 @default.
• W2099681868 cites W2059032411 @default.
• W2099681868 cites W2062911233 @default.
• W2099681868 cites W2064544547 @default.
• W2099681868 cites W2072079162 @default.
• W2099681868 cites W2077995563 @default.
• W2099681868 cites W2082610063 @default.
• W2099681868 cites W2089267976 @default.
• W2099681868 cites W2095649647 @default.
• W2099681868 cites W2103172719 @default.
• W2099681868 cites W2103526359 @default.
• W2099681868 cites W2106107148 @default.
• W2099681868 cites W2111541375 @default.
• W2099681868 cites W2113606874 @default.
• W2099681868 cites W2119963782 @default.
• W2099681868 cites W2120448591 @default.
• W2099681868 cites W2130538948 @default.
• W2099681868 cites W2149865992 @default.
• W2099681868 cites W2157330336 @default.
• W2099681868 cites W2164472870 @default.
• W2099681868 cites W2167980932 @default.
• W2099681868 cites W4229889425 @default.
• W2099681868 doi "https://doi.org/10.1210/me.2004-0401" @default.
• W2099681868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16423882" @default.
• W2099681868 hasPublicationYear "2006" @default.
• W2099681868 type Work @default.
• W2099681868 sameAs 2099681868 @default.
• W2099681868 citedByCount "19" @default.
• W2099681868 countsByYear W20996818682012 @default.
• W2099681868 countsByYear W20996818682013 @default.
• W2099681868 countsByYear W20996818682014 @default.
• W2099681868 countsByYear W20996818682016 @default.
• W2099681868 countsByYear W20996818682017 @default.
• W2099681868 crossrefType "journal-article" @default.
• W2099681868 hasAuthorship W2099681868A5005692759 @default.
• W2099681868 hasAuthorship W2099681868A5011763388 @default.
• W2099681868 hasAuthorship W2099681868A5015580865 @default.
• W2099681868 hasAuthorship W2099681868A5016640394 @default.
• W2099681868 hasAuthorship W2099681868A5020285542 @default.
• W2099681868 hasAuthorship W2099681868A5021075431 @default.
• W2099681868 hasAuthorship W2099681868A5042201449 @default.
• W2099681868 hasAuthorship W2099681868A5050075947 @default.
• W2099681868 hasAuthorship W2099681868A5063165070 @default.
• W2099681868 hasAuthorship W2099681868A5078763633 @default.
• W2099681868 hasAuthorship W2099681868A5080276064 @default.
• W2099681868 hasAuthorship W2099681868A5080763146 @default.
• W2099681868 hasConcept C104317684 @default.
• W2099681868 hasConcept C121608353 @default.
• W2099681868 hasConcept C126322002 @default.
• W2099681868 hasConcept C1292079 @default.
• W2099681868 hasConcept C134018914 @default.
• W2099681868 hasConcept C150194340 @default.
• W2099681868 hasConcept C153911025 @default.
• W2099681868 hasConcept C170493617 @default.
• W2099681868 hasConcept C2777911890 @default.
• W2099681868 hasConcept C2779723316 @default.
• W2099681868 hasConcept C2780192828 @default.
• W2099681868 hasConcept C502942594 @default.
• W2099681868 hasConcept C530470458 @default.

• next